Biocon Bets Big on Insulin and GLP-1 Drugs to Expand Market Reach

India’s biopharmaceutical sector is witnessing a significant shift as Biocon intensifies its dual focus on insulin and GLP-1 therapies, positioning itself strongly in two high-growth segments. With decades of expertise in biosimilar insulins, the Bengaluru-based company is now advancing aggressively in the GLP-1 space, targeting the expanding market for drugs that address both glucose control and weight management.

Biocon has completed bioequivalence studies in India for semaglutide, a GLP-1 drug, and is moving to Phase-III trials, expected to conclude by the end of 2026. “Subsequent regulatory approval is anticipated in CY 2027, after which we will launch the product in India through a partner,” said Shreehas Tambe, CEO and managing director of Biocon Biologics. Novo Nordisk’s semaglutide (Wegovy) goes off patent in India in March, opening a critical market window.

“The disruption (due to GLP-1) is complementary to insulin. We are bullish on both insulin and GLP-1,” Tambe said, adding that synergy exists in therapy areas, operations, and market touchpoints. Biocon’s strength lies in its dual portfolio—biosimilar insulins and GLP-1 peptides—along with its expertise in injectable drug delivery and patient support, honed over years in 80-plus countries.

Also Read: Biocon Targets Canada's Lucrative Market for Ozempic, Wegovy Generics

The company recently secured US FDA approval for insulin aspart, expanding its US market presence after Semglee, and plans to launch it by the fiscal year’s end. In June, it gained Indian approval for liraglutide, already marketed in the UK and EU.

“The biggest concern for the year ahead is external risks to the business, such as potential tariff and geopolitical headwinds… but that is the biggest concern for the whole industry too,” Tambe cautioned.